EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC 3.0

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Administration JMKX003142 in Chinese Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Single, and Multiple Ascending Dose Phase I Clinical Trial

Cheng Cui, Jixiang Zhu, Zhiping Liu, Jingyao Liu, Xiaomin Huang, Yi Liu, Jingqiu Hu, Lingli Zhang, Xue Zhang, Yila Sha, Dongyang Liu iD, Haiyan Li

Drug Design, Development and Therapy · 2026-03 · Volume 20 · 1-19

DOI: 10.2147/dddt.s583445 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Drug Design, Development and Therapy, 2026-03. Verfasst von Cheng Cui und 11 weiteren Autor:innen. Beteiligte Einrichtung: Drug Clinical Trial Center, Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, People's Republic of China. Hauptthemen laut MEDLINE: Receptors, Vasopressin, Antidiuretic Hormone Receptor Antagonists. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, VasopressinAntidiuretic Hormone Receptor AntagonistsAdultFemaleHumansMaleYoung AdultAdministration, IntravenousChinaDose-Response Relationship, DrugDouble-Blind MethodHealthy VolunteersInjections, IntravenousEast Asian People

Stichwörter der Autor:innen

JMKX003142active arginine vasopressin V2 receptor antagonistpharmacodynamicspharmacokineticssafetytolerability

Substanzen

AVPR2 protein, humanReceptors, VasopressinAntidiuretic Hormone Receptor Antagonists

Autor:innen und Institutionen

  • Drug Clinical Trial Center, Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, People's Republic of China.
  • Center of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, People's Republic of China.
  • Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, Peking University Third Hospital, Beijing, 100191, People's Republic of Chin…
  • Clinical Development Center, Shanghai Jeyou Pharmaceutical Co.,Ltd., Shanghai, 200120, People's Republic of China.

ORCID-Profile: Dongyang Liu

Zitieren

APA

Cui, C., Zhu, J., Liu, Z., Liu, J., Huang, X., Liu, Y., Hu, J., Zhang, L., Zhang, X., Sha, Y., Liu, D., & Li, H. (2026). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Administration JMKX003142 in Chinese Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Single, and Multiple Ascending Dose Phase I Clinical Trial. Drug Design, Development and Therapy, Volume 20, 1-19. https://doi.org/10.2147/dddt.s583445

Vancouver

Cui C, Zhu J, Liu Z, Liu J, Huang X, Liu Y, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Administration JMKX003142 in Chinese Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Single, and Multiple Ascending Dose Phase I Clinical Trial. Drug Design, Development and Therapy. 2026;Volume 20:1-19. doi:10.2147/dddt.s583445

BibTeX
@article{Cui2026,
  author = {Cui, Cheng and Zhu, Jixiang and Liu, Zhiping and Liu, Jingyao and Huang, Xiaomin and Liu, Yi and Hu, Jingqiu and Zhang, Lingli and Zhang, Xue and Sha, Yila and Liu, Dongyang and Li, Haiyan},
  title = {Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Administration JMKX003142 in Chinese Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Single, and Multiple Ascending Dose Phase I Clinical Trial},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  volume = {Volume 20},
  pages = {1--19},
  doi = {10.2147/dddt.s583445}
}
Kostenlos starten →